英国50岁及以上乳腺癌患者每年与低频钼靶监测的比较(Mammo-50):一项多中心、随机、3期、非劣效性试验
Mammo-50多中心随机3期非劣效试验纳入5235例50岁及以上、根治术后3年无复发的乳腺癌患者,1:1随机接受每年或低频钼靶监测。中位随访5.7年,5年乳腺癌特异性生存率每年组98.1% vs 低频组98.3%(HR 0.92,95%CI 0.64-1.32),低频钼靶在预设3%界值下非劣效(非劣效p<0.0001)。
要点
- 50岁及以上乳腺癌患者根治术后3年,低频钼靶监测在乳腺癌特异性生存方面非劣于每年钼靶。
- 5年乳腺癌特异性生存率每年组98.1% vs 低频组98.3%(HR 0.92,95%CI 0.64-1.32)。
- 5年无复发生存率每年组94.1% vs 低频组94.5%,5年总生存率每年组94.7% vs 低频组94.5%。
核心结论
- 对于50岁及以上、诊断后3年的患者,低频钼靶在乳腺癌特异性生存、无复发生存和总生存方面非劣于每年钼靶,应考虑用于该人群。
研究设计与样本
- Mammo-50为多中心、随机、3期非劣效性试验,在英国114家国民健康服务体系医院开展。
- 纳入50岁及以上、初诊为浸润性或非浸润性乳腺癌、根治性手术后3年无复发的女性,1:1随机分配至每年或低频钼靶(保乳术后2年一次;乳房切除术后3年一次),随访6年。
- 共5235例女性随机分配至每年钼靶组(n=2618)或低频钼靶组(n=2617);3858例(73.6%)年龄60岁及以上,4202例(80.3%)接受保乳手术,4576例(87.4%)为浸润性疾病,1159例(22.1%)淋巴结阳性,4330例(82.7%)雌激素受体阳性肿瘤。
- 共同主要结局为乳腺癌特异性生存和成本效果;成本效果分析将另文报告;乳腺癌特异性生存在意向治疗人群中评估。
- 5000例女性提供90%把握度,以2.5%单侧显著性水平检测乳腺癌特异性生存的3%绝对非劣效界值。
主要发现
- 中位随访5.7年(IQR 5.0-6.0;根治性手术后8.7年),343例死亡,其中116例死于乳腺癌(每年钼靶组61例,低频钼靶组55例)。
- 5年乳腺癌特异性生存率每年钼靶组98.1%(95%CI 97.5-98.6) vs 低频钼靶组98.3%(97.8-98.8),风险比HR 0.92(95%CI 0.64-1.32),在预设3%界值下证明低频钼靶非劣效(非劣效p<0.0001)。
- 5年无复发生存率每年钼靶组94.1%(95%CI 93.1-94.9) vs 低频钼靶组94.5%(93.5-95.3)。
- 5年总生存率每年钼靶组94.7%(95%CI 93.8-95.5) vs 低频钼靶组94.5%(93.5-95.3)。
- 345例乳腺癌事件中224例(64.9%)通过急诊入院或症状转诊回医院系统发现,其中每年钼靶组175例中108例(61.7%),低频钼靶组170例中116例(68.2%)。
关键数值与推荐
- 非劣效界值为乳腺癌特异性生存的3%绝对差异,单侧显著性水平2.5%。
- 低频钼靶方案:保乳术后每2年一次,乳房切除术后每3年一次。
临床怎么用
- 作者认为,对于50岁及以上、诊断后3年的患者,应考虑采用低频钼靶监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The frequency of mammographic surveillance for women after diagnosis of breast cancer varies globally. The aim of this study was to evaluate whether less than annual mammography was non-inferior in terms of breast cancer-specific survival in women aged 50 years or older. METHODS: Mammo-50 was a multicentre, randomised, phase 3 trial of annual versus less frequent mammography (2-yearly after conservation surgery; 3-yearly after a mastectomy) for women aged 50 years or older at initial diagnosis of invasive or non-invasive breast cancer and who were recurrence free 3 years post curative surgery. The trial was conducted at 114 National Health Service hospitals in the UK. Participants were randomly assigned (1:1) to annual or less frequent mammograms at 3 years post curative surgery and were followed up for 6 years. The co-primary outcomes were breast cancer-specific survival and cost-effectiveness. The cost-effectiveness analysis will be reported elsewhere. Breast cancer-specific survival was assessed in the intention-to-treat population. Secondary outcomes were recurrence-free interval, overall survival, and referrals back to the hospital system. 5000 women provided 90% power to detect a 3% absolute non-inferiority margin for breast cancer-specific survival with 2·5% one-sided significance. The trial was registered with the ISRCTN registry, ISRCTN48534559; recruitment is complete but longer-term follow-up is ongoing. FINDINGS: Between April 22, 2014, and Sept 28, 2018, 5235 women were randomly assigned to annual mammography (n=2618) or less frequent mammography (n=2617). 3858 (73·6%) women were aged 60 years or older, 4202 (80·3%) had undergone conservation surgery, 4576 (87·4%) had invasive disease, 1159 (22·1%) had node positive disease, and 4330 (82·7%) had oestrogen receptor-positive tumours. With a median of 5·7 years follow-up (IQR 5·0-6·0; 8·7 years post curative surgery), 343 women died, including 116 who died of breast cancer (61 in the annual mammography group and 55 in the less frequent mammography group). 5-year breast cancer-specific survival was 98·1% (95% CI 97·5-98·6) in the annual mammography group and 98·3% (97·8-98·8) in the less frequent mammography group (hazard ratio 0·92, 95% CI 0·64-1·32), demonstrating non-inferiority of less frequent mammography at the pre-specified 3% margin (non-inferiority p<0·0001). 5-year recurrence-free interval was 94·1% (95% CI 93·1-94·9) in the annual mammography group and 94·5% (93·5-95·3) in the less frequent mammography group. Overall survival at 5 years was 94·7% (95% CI 93·8-95·5%) and 94·5% (93·5-95·3), respectively. 224 (64·9%) of 345 breast cancer events were detected from emergency admissions or symptomatic referrals back to the hospital system, including 108 (61·7%) of 175 in the annual mammography group and 116 (68·2%) of 170 in the less frequent mammography group. INTERPRETATION: For patients aged 50 years or older and at 3 years post diagnosis, less frequent mammograms were non-inferior compared with annual mammograms for breast cancer-specific survival, recurrence-free interval, and overall survival, and should be considered for this population. FUNDING: National Institute for Health Research Health Technology Assessment programme.
引用
- Dunn JA, Donnelly P, Elbeltagi N, et al. Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial. Lancet. 2025. PMID: 39892911. doi:10.1016/S0140-6736(24)02715-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。